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Introduction 14 
Since the publication of the first shotgun sequenced genome (cauliflower mosaic virus1), the 15 
draft human genome2 and the first bacterial genomes (Haemophilus influenzae3 and 16 
Mycoplasma genitalium3), combined with the rapidly falling cost of high-throughput 17 
sequencing4, genomics has become a major contributor to our understanding of human and 18 
pathogen biology. Multiple large scale systematic pathogen genome projects have been 19 
recently completed or are on-going (e.g. sequencing thousands of microbiomes and fungal 20 
genomes5,6); these projects are shaping our knowledge of the genetic variation present in human 21 
and pathogen populations, the nature of genetic changes that underlie disease, and the sheer 22 
diversity of microorganisms with which we share our environments. 23 
The methods and data from whole genome sequencing are increasingly being applied to clinical 24 
medicine, both from a human7 and pathogen perspective. For example whole-pathogen genome 25 
sequencing has been used to identify new routes of Mycobacterium abscessus8 nosocomial 26 
transmission and to understand Neisseria meningitidis epidemics in Africa9, while partial 27 
genome sequencing has been used to detect drug resistance in RNA viruses such as influenza10 28 
and DNA viruses such as human cytomegalovirus (HCMV)11. Viral genome sequencing has 29 
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gained considerable traction, often focused on research or epidemiology. Whole pathogen 30 
genome sequencing has the advantage of detecting all known drug resistance mutations in a 31 
single test while deep sequencing can identify low level drug resistance mutations early enough 32 
for clinical intervention12,13. Whole genomes also provide good data with which to identify 33 
linked infections for public health and infection control purposes14,15. Notwithstanding, 34 
progress in whole-genome sequencing (WGS) of viruses for clinical practice has been slow. In 35 
contrast whole-genome sequencing of bacteria is now well accepted particularly for outbreak 36 
tracking and for the management of nosocomial transmission of antimicrobial resistant 37 
bacteria16,17.   38 
This review will address the challenges and opportunities for making WGS, using modern next 39 
generation sequencing (NGS) methods, a standard part of clinical virology practice. We will 40 
discuss the strengths, weaknesses and technical challenges inherent to different viral WGS 41 
laboratory methods (Table 1). The importance of deeply sequencing certain viral pathogens 42 
will be addressed. We will also explore two areas in which viral WGS has recently proven its 43 
clinical utility: metagenomic sequencing to identify viruses causing encephalitis (box 1); and 44 
role of WGS in molecular epidemiology and public health management of the pan-American 45 
Zika virus outbreak (box 2). Finally, we will briefly consider the ethical and data analysis 46 
challenges which clinical viral WGS presents. 47 
 48 
Why sequence viruses in clinical practice?  49 
For small viruses such as HIV, influenza, HBV and HCV, partial genome sequencing has been 50 
widely used for research purposes, but also has important clinical applications. For example, 51 
the management of highly active anti-retroviral therapy (HAART) for HIV relies heavily on 52 
viral sequencing for detection of mutations conferring drug resistance.  HAART has 53 
dramatically improved survival of patients with HIV, but successful therapy requires long-term 54 
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suppression of viral replication with anti-retroviral drugs, which may be prevented by impaired 55 
host immunity, sub-optimal drug penetration to host tissue compartments and incomplete 56 
patient adherence to therapy18. Where viral replication continues to occur, the high mutation 57 
rate of HIV enables resistance variants to emerge. It has become standard practice in many 58 
parts of the world to sequence the HIV pol gene, which encodes the main viral enzymes, for 59 
mutations conferring resistance to inhibitors of reverse transcriptase, integrase and protease19, 60 
particularly when patients are first diagnosed and when viral loads indicate treatment failure. 61 
Sequencing resistance mutations has allowed more targeted alterations in treatment with 62 
significantly greater reductions in virus loads compared with  standard care (undetectable HIV 63 
load in 32% vs 14% of patients after six months)20,21. Thus sequencing resistance mutations to 64 
guide HIV treatment improves disease outcomes. Similar approaches have been taken for 65 
identifying HCV22, HBV23, and influenza24 resistance mutations. 66 
 67 
Why sequence whole genomes? 68 
Limited sequencing of the small number of genes that are targeted by anti-viral agents, such as 69 
the HIV polymerase gene, has hitherto been the norm in clinical practice.  For detecting a 70 
limited number of antiviral resistance mutations, WGS has been too costly and labour-intensive 71 
to justify. However, the increase in numbers of antivirals targeting genes that are located across 72 
the genome, coupled with falling costs of sequencing and the use of sequence data for 73 
transmission studies, are driving a reappraisal of the need for WGS. For example, antiviral 74 
treatment for HCV now targets four gene products (NS3, NS4A, NS5A, NS5B) encoded by 75 
more than 50% of the viral genome25. Separate targeted sequencing for each of these can be as 76 
expensive and time consuming as WGS26. Partial genome sequencing is particularly 77 
problematic for larger viral genomes most notably those of the herpesviruses HCMV11, VZV27, 78 
HSV-128 and -229. These have traditionally been treated with drugs targeting the 79 
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protein/thymidine kinase and DNA polymerase genes. However the growing numbers of drugs 80 
in development that interact with different proteins encoded by viral genes scattered across the 81 
genome, means that the targeted sequencing of multiple genes required for resistance testing is 82 
costly and less tractable30. Sequencing the whole genome captures all resistance mutations 83 
simultaneously and obviates the need to design and optimise new PCR assays for detecting 84 
resistance to new drugs. A good example of this is HCMV, where WGS can simultaneously 85 
capture the genes with products targeted by the licensed therapies such as UL27 (unknown 86 
function), UL54 (DNA polymerase), and UL97 (protein kinase), as well as newer drugs such 87 
as letermovir which targets UL56 (terminase complex), enabling comprehensive anti-viral 88 
resistance testing in a single test11. At the same time WGS has the potential to provide 89 
information on epitopes, evolution of sequences within a patient over time11, and evidence of 90 
recombination between HCMV strains31. WGS can highlight putative novel drug resistance 91 
mutations, or predicted changes to epitopes, although phenotypic testing of any findings in a 92 
model system is required to confirm clinical resistance (e.g. 32) or to map epitope changes (e.g. 93 
33).   94 
As  pre-existing resistance to anti-viral drugs (for example, protease inhibitor-resistant HCV34 95 
and nucleoside analog reverse transcriptase inhibitor-resistant HBV35) increases, whole 96 
genome sequences will provide the comprehensive resistance data required for selecting 97 
appropriate treatment to achieve good patient outcomes. A complete knowledge of all 98 
resistance mutations can also support more radical management decisions. In a recent case 99 
report, identification of extensive genome-wide HCMV drug resistance within a patient 100 
supported the clinical decision to change to immunotherapeutic treatments, specifically 101 
autologous cytomegalovirus-specific T cells36.  102 
Whole genomes may also better identify transmission events and outbreaks, which is not 103 
always possible with sub-genomic fragments. For example, sequencing respiratory syncytial 104 
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virus (RSV) genomes demonstrated that variation was present outside the gene traditionally 105 
used for genotyping, and could be used to help track outbreaks within households, where there 106 
had been insufficient time for single genes to accumulate enough genetic variability to be used 107 
for transmission studies37.  The increased number of phylogenetically informative variant sites 108 
obtained from generating full or near full length genomes has been shown to obviate the need 109 
for high quality sequences, allowing robust linking of Ebola cases and public health 110 
interventions in real time during the recent epidemic38. This also applies to Zika virus, and Box 111 
2 explores the role of WGS in public health efforts to control the outbreak in South America.  112 
The increased use of whole pathogen sequencing routinely for diagnostic purposes39 is likely 113 
to have wider clinical and research benefits.  For example HIV genome sequencing to identify 114 
resistance mutations, can also be used to explore questions related to viral evolution40, public 115 
health41 and viral genetic association with disease. This includes well-powered genotype-116 
phenotype association studies or genome-to-genome association studies, which look for 117 
associations between viral genetic variants, host genetic variants, and outcomes of infection, 118 
such as viral load set point in HIV infection42.  119 
 120 
Why do we need deep sequencing?  121 
Modern methods which make use of massively parallel sequencing provide better opportunities 122 
to examine pathogen diversity through analysis of viral populations within or between hosts 123 
that contain nucleotide variants or haplotypes at low (sub-consensus, less than 50%) 124 
frequencies. Minority variant analysis is particularly powerful for RNA or retro-transcribing 125 
viruses, because they typically have high within-host nucleotide diversity. HIV is the classic 126 
example; the viral replication cycle utilises an error-prone reverse transcriptase enzyme that 127 
introduces mutations at an extremely high rate (4.1 ± 1.7 × 10−3 per base per cell)43. This results 128 
in a given patient containing not one, but many closely related viruses each bearing subtly 129 
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different variants, sometimes described as a quasispecies or cloud of intra-host viral diversity. 130 
The presence of a mixed population of viruses introduces problems for determining the true 131 
consensus ‘majority’ sequence, but these minority (non-consensus) variants may also alter the 132 
clinical phenotype of the virus, or predict changes in genotype, tropism or drug resistance. For 133 
example, a minor variant conferring drug resistance in HIV present at only 2.1% of sequencing 134 
reads in a baseline patient sample can rapidly rise to become a majority (consensus) variant 135 
under the selective pressure of drug treatment44. Investigators have observed similar changes 136 
in frequency of resistance-associated alleles during treatment of viruses such as HBV45, HCV46, 137 
HCMV11 and influenza47.  138 
Sensitive deep-sequencing of viruses is not only required to detect drug resistance: for HIV, it 139 
is also key in genotypic prediction of receptor tropism, which has clinical implications in 140 
treatment of HIV. HIV can be grouped genotypically by its cellular co-receptor usage as R5 141 
(CCR5-using), X4 (CXCR4-using) or R5X4 (dual tropism). Maraviroc is a CCR5 receptor 142 
antagonist, blocking infection by R5-tropic HIV genotypes, but contraindicated in HIV+ 143 
individuals who have X4 or R5X4 HIV genotypes. Just a 2% frequency of X4 or R5X4 144 
genotypes is predictive of maraviroc treatment failure48. Sub-consensus frequencies of X4 or 145 
R5X4 HIV are also important to the success49 or failure50 of bone marrow transplants from 146 
CCR5-deleted (CCR5-Δ32) donors. This may influence decisions to continue or stop anti-viral 147 
therapy in these patients49.  148 
Detection of minority variants and haplotype identification may also detect mixed infections. 149 
In HCMV mixed-genotype infections or super-infections51 are associated with poor clinical 150 
outcomes - detection of these by WGS might support a decision to treat disease in these patients 151 
more aggressively. 152 
Establishing the clinical associations of minority variants is clearly important, as with 153 
maraviroc treatment failure; Sanger sequencing of a virus population can detect minority 154 
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variants down to frequencies of between 10 and 40% (e.g. 52), whilst NGS can sequence those 155 
same PCR amplicons to a much greater depth53, and consequently capture more of the 156 
variability present. Thresholds of sensitivity and specificity established need to be specific to 157 
the virus in question, and reflect the potential biases of the sequencing methods used. Many 158 
studies of HIV drug resistance utilising deep-sequencing of PCR amplicons require minority 159 
variants to be present at >1%, to reduce the possibility of false positives54,55. This may lead to 160 
a failure to detect true drug resistance mutations at frequencies of 0.1%-1%, which may 161 
ultimately be associated with poor treatment outcome on some drug regimes55. While a 1-2% 162 
frequency threshold (or lower) may be clinically relevant to drug resistance in HIV, it is less 163 
clear whether the same degree of sensitivity would be required for monitoring vaccine escape 164 
in HBV or drug resistance in herpesvirues (discussed below). Large cohorts of patients will 165 
need to be followed with samples collected before, during and after treatment44,48, to establish 166 
clinical significance thresholds for minority drug resistance11 and vaccine escape variants for 167 
each virus.   168 
Direct deep sequencing of clinical material, either by shotgun or RNAseq methods (so called 169 
metagenomic methods) also provides the opportunity for unbiased detection of pathogen 170 
sequences and thus primary diagnosis of viral and other infections, thereby providing an 171 
alternative to culture, electron microscopy and qPCR. This is discussed further below.   172 
 173 
Practical considerations for sequencing virus genomes 174 
As previously alluded to, sequencing viral nucleic acid whether cultured or directly from 175 
clinical specimens, is complicated by the presence of contaminating host DNA56.  This makes 176 
it different from bacterial sequencing which is easily carried out using clinical isolates and thus 177 
sample preparation is relatively straightforward (Table 2). Currently, genome sequencing of 178 
viruses can be achieved by ultradeep sequencing or by enriching for viral nucleic acid prior to 179 
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sequencing either directly or through prior concentration of viral particles.  All approaches 180 
have their own costs and complexities.    181 
 182 
The three primary methods currently used for viral genome sequencing are summarised in 183 
Figure 1. 184 
 185 
(i) Metagenomics - ultra deep sequencing 186 
 187 
Metagenomic approaches have been extensively used for pathogen discovery and for 188 
characterising microbial and general pathogen diversity in environmental and clinical  189 
samples57,58. Total DNA and/or RNA from a sample, including from host, bacteria, viruses, 190 
fungi and other pathogens present are extracted, put through library preparation and sequenced 191 
by ‘shotgun’ or RNA-seq methods (see Box 1). These approaches have proven to be very 192 
powerful for detecting viral59,60,61 and other causes62 of encephalitis where other conventional 193 
methods such as PCR have failed. Box 1 explores the growing diagnostic applications for 194 
metagenomics and RNAseq, for example in encephalitis of unknown aetiology (e.g.63-65). In 195 
addition, a number of whole viral genomes have been sequenced in this manner, including 196 
Epstein-Barr virus (EBV)66 and HCV26.  However, these methods may be insensitive, because 197 
of the presence of contaminating host and commensal pathogen nucleic acid56 (Table 2) in 198 
clinical specimens.  For example on-target read yields (the proportion of reads matching the 199 
target genome) from metagenomic WGS of 0.008% (EBV genome from the blood of a healthy 200 
adult67), 0.0003% (lassa virus genomes from clinical samples68) and 0.3% (a filtration and 201 
centrifugation enriched Zika virus sample69) have been reported. The read depths obtained are 202 
often inadequate for robust resistance calling26 and the cost is high. Thus the method has 203 
typically only been performed on a small number of samples for research purposes (e.g.69,70). 204 
To improve read depths, concentration of viral particles prior to sequencing (as for example in 205 
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the Zika case69), depletion of host material or ultra-deep sequencing have been employed, all 206 
of which add to the cost. Concentrating viral particles from clinical specimens by antibody-207 
mediated pulldown (e.g. VIDISCA), filtration, or ultracentrifugation, to isolate a fragment size 208 
profile, and depletion of free nucleic acid71-74 have all been tried. These host nucleic acid 209 
depletion methods may result in there being insufficient viral nucleic acid for sequencing 210 
library preparations. To overcome this, non-specific amplification methods (e.g. multiple 211 
displacement amplification; MDA) which make use of random primers and phi 29 polymerases 212 
may be effective in increasing DNA load.  However, these approaches are time consuming, 213 
costly, and may increase the risk of biases, error and contamination without necessarily 214 
improving the sensitivity of sequencing75,76. Moreover, there are often still a high proportion 215 
of host reads present in treated samples77.   216 
Where metagenomic methods are used for pathogen discovery or diagnosis, appropriate 217 
bioinformatic tools and databases capable of evaluating whether detected pathogens sequences 218 
are truly likely to be the cause of infection, innocent bystanders or contaminants are critical. 219 
Bioinformatic analyses of large metagenomic datasets places an increased burden on high 220 
performance computational resources.  221 
The fact that metagenomics requires no prior knowledge of the viral genome, can be considered 222 
a strength26 in that it allows novel viruses to be sequenced without the need for primer or probe 223 
design and synthesis. This is particularly apposite for rapid responses to emerging threats such 224 
as Zika78. Metagenomic viral genome sequencing may also ‘piggy back’ on projects to 225 
sequence virus-associated cancer genomes, which informs clinical care of the cancer or 226 
provides further information on cancer evolution, while generating high coverage of integrated 227 
virus genomes as part of the process66.  However, the presence of incidental findings (human 228 
genome sequences with potential disease associations, pathogens which were not part of the 229 
question that prompted the initial sequencing) may also present ethical (and even diagnostic) 230 
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dilemmas for some applications of clinical metagenomics (discussed below and reviewed in 231 
79). A recent case in point was a cluster of acute flaccid myelitis cases associated with 232 
enterovirus D6880. The analysis of the metagenomic datasets derived from patients was the 233 
subject of discussion through formal81 and informal scientific channels 234 
(http://omicsomics.blogspot.co.uk/2015/07/leaky-clinical-metagenomics-pipelines.html), with 235 
different groups disagreeing over the interpretation of the same data, especially as some of the 236 
alternative pathogens detected can cause treatable bacterial disease. Regulation and reporting 237 
frameworks will be important to resolve future issues of this kind. 238 
 239 
(ii) PCR amplicon enrichment,  240 
An alternative to metagenomic approaches is to enrich for the specific viral genome prior to 241 
sequencing. PCR amplification of hundreds to thousands of base pairs of viral genetic material 242 
using primers that are complementary to a known nucleotide sequence has been the most 243 
common approach to enriching for small viral genomes such as HIV and influenza, prior to 244 
NGS sequencing for diagnostic and public health purposes. Recent examples of this approach 245 
being applied for public health include sequencing measles virus by PCR-WGS to provide 246 
maximum phylogenetic resolution of an outbreak at the 2010 Winter Olympics82, sequencing 247 
of Ebola virus genome to study epidemic dynamics38, and Zika virus genome sequencing 248 
(explored in Box 2). PCR whole-genome sequencing of norovirus (7.5kb genome) has been 249 
used to understand norovirus transmission in community83 and hospital84 settings. For example, 250 
this research showed that some cases within a hospital with plausible epidemiological linkage 251 
were in fact independent introductions of the pathogen; but that other cases were the result of 252 
transmission, despite infection control practices being in place84. Other PCR-based deep 253 
sequencing studies have generated multiple whole genomes for influenza85 (~13.5kb), dengue86 254 
(~11kb), and HCV87 (9.6kb). This method is feasible (as with PCR and Sanger sequencing) 255 
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because these viruses all have relatively small genomes, requiring only a small number of PCR 256 
amplicons to assemble whole genome sequences. RNA virus heterogeneity may however 257 
necessitate the use of multiple overlapping primer sets to ensure comprehensive amplification 258 
of all genotypes, for example HCV26, norovirus83, rabies88 and RSV37. PCR amplicon 259 
sequencing is also more successful for WGS of samples with low virus loads than metagenomic 260 
methods26, although other methods such as target enrichment of viral sequences may work 261 
equally well in low copy number samples (e.g. low copy norovirus samples89). 262 
Overlapping PCRs combined with NGS have been used to sequence the whole genomes of 263 
larger viruses such as HCMV90, but this overlapping amplicon method has limited scalability, 264 
since many primers are needed90 and a greater amount of starting DNA to allow for each 265 
additional PCR, which may not be available from clinical samples. This limits the number of 266 
suitable samples available and also the genomes which can be studied with this method. A 267 
molecular epidemiology study of the relatively small Ebola genome required between 8 and 19 268 
PCR products to amplify the genome for MinION nanopore sequencing38, whilst 1483 and 22 269 
pairs84 of primers were needed to amplify and Illumina sequence norovirus genomes. This 270 
becomes less practical in a clinical rather than research setting because of the high laboratory 271 
workload associated with large numbers of discrete PCR reactions, the necessity for 272 
individually normalising concentrations of different PCR amplicons prior to pooling, the 273 
increasing probability of reaction failure due to primer mismatch, particularly in very variable 274 
genomes and the increasing labour and consumables cost associated with multiple PCR 275 
reactions91. Therefore, although PCR-based sequencing of viruses as large as 250 Kb is 276 
technically possible, the proportional relationship between genome size and technical 277 
complexity make PCR sequencing of sequencing viral genomes beyond 20 - 50 Kb impractical 278 
with current technologies, particularly with regards to large multi-sample studies or routine 279 
diagnostics. Another consideration is that increasing PCR reactions require a corresponding 280 
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increase in available sample, and this is not always possible where clinical specimens are 281 
limited. Improvements in microfluidic technologies may help to overcome some of these 282 
barriers to PCR-based methods, for example Fluidigm, RainDance and other ‘droplet’ 283 
sequencing technologies. Microfluidics-based PCR and pooling of multiple amplicons have 284 
been used successfully to sequence multiple anti-microbial resistance loci, for example92, and 285 
can also applied to viral genomes, potentially down to the single-cell sequencing level.  286 
PCR may encounter problems in amplifying highly variable pathogens such as HCV93 and 287 
norovirus where there are many different genotypes, with some genotypes encountering primer 288 
amplification issues26,89, or where there is insufficient characterisation of intra-genotypic 289 
diversity, leading to primer mis-matches83. Careful design of degenerate primers may help to 290 
mitigate these problems, but novel variants still present a risk to detection and amplification. 291 
 292 
(iii) Target Enrichment methods  293 
Target enrichment (TE) methodologies (also known as pulldown, capture or specific 294 
enrichment methods) represent one solution to problems of PCR or metagenomic sequencing 295 
of virus genomes. We and a number of other groups have been developing methods that can be 296 
used to sequence whole viral genomes directly from clinical samples without the need for prior 297 
culture or PCR94-96. These methods typically involve small RNA/DNA probes designed to be 298 
complementary to the pathogen reference sequence (or panel of references). Unlike in specific 299 
PCR amplicon based methods, the entire genome can be covered by a single tube of 300 
overlapping probes which are used in a hybridisation reaction to capture or ‘pull down’ 301 
complementary DNA sequences bound to a solid phase (e.g. streptavidin-labelled magnetic 302 
beads) from the total nucleic acids present in a sample, followed by sequencer-specific (e.g. 303 
Illumina) adaptor ligation and a small number of PCR cycles to enrich for successfully ligated 304 
fragments. This has been used successfully to characterise large and small clinically relevant 305 
viruses such as HCV26, HSV197, VZV96, EBV98, CMV66, HHV699 and HHV7100. The reaction 306 
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is performed in a single well and, like microfluidics-based PCR reactions, is amenable to high 307 
throughput automation98. The lack of a culture step means that the sequences obtained are more 308 
representative of original virus than cultured viral isolates, with fewer mutations than observed 309 
in PCR amplified templates66,96. The success of this method is in part based on the number of 310 
available reference sequences for the virus of interest: specificity increases when baits are 311 
designed against a larger panel of reference sequences, leading to better capture of the breadth 312 
of within and between sample diversity. TE probe design allows for limited mismatching 313 
between template and probe, but whilst PCR requires only knowledge of flanking regions of a 314 
target region, TE requires knowledge of the internal sequence in order to design baits. This is 315 
balanced by the fact that TE is less vulnerable to a single amplicon failure due to mismatch as 316 
internal and overlapping regions may still be captured even if one probe fails66,96. As such TE 317 
is not suitable for characterisation of novel viruses with low homology to known viruses, where 318 
metagenomics (or in some cases, PCR using degenerate primers), may be more appropriate. 319 
As with all methods, the technique is also subject to constraints with regard to starting viral 320 
load. We have shown that although capable of sequencing virus from viral loads as low as 2000 321 
IU/ml (HCV) or 2500 IU/ml (HCMV), targets could only be enriched so much, leading to 322 
reduced depth of coverage in sequencing data at lower viral concentration26,66. With 323 
metagenomics, the proportion of sequencing data mapping to the pathogen genome (the on-324 
target read percentage) that can be expected from unenriched sequencing of clinical samples is 325 
small. Depending upon the starting pathogen load in a sample, TE can enrich percentage on-326 
target viral reads from 0.01% up to 80% or more66. This allows a higher degree of multiplexing 327 
than unenriched metagenomics, and brings an accompanying decrease in the price of 328 
sequencing, albeit with a relative increase in the cost of library preparation. There are 329 
alternative approaches to enriching viral reads which include pulse-field gel electrophoresis101, 330 
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which separates large viral genomes from smaller host DNA fragments, allowing for 331 
sequencing libraries composed of a smaller proportion of contaminating host DNA. 332 
Enrichment techniques which make use of degenerate RNA or DNA probes to hundreds of 333 
viral species to pull viral nucleic acid out of samples and sequence them, e.g.the VirCapSeq 334 
method, have also been developed102. This method is designed for detection of both known and 335 
novel viruses, although its performance remains to be evaluated. 336 
 337 
Comparison of all three methods 338 
To date, there has been very little direct comparison between the three methods for viral 339 
genome sequencing in clinical practice, with only one paper evaluating relative performance 340 
for HCV sequencing26. Results from this study, in which three different enrichment protocols, 341 
two metagenomic methods and one overlapping PCR method were evaluated, showed that 342 
metagenomic methods were the least sensitive, yielding the lowest genome coverage for 343 
comparable sequencing effort and were more prone to yield incomplete genome assemblies. 344 
The PCR method was the least tractable and most labour intensive, requiring repeated 345 
amplification and was the most likely to miss mixed infections, but where reactions were 346 
successful, yielded the most consistent read depth, whereas metagenomics and TE yielded read 347 
depths in proportion to virus copy number. Some HCV genotypes (particularly genotype 2) 348 
were more prone to generate incomplete sequences when PCR was used instead of 349 
metagenomics or TE. Targeted enrichment was the most consistent method, achieving full 350 
genomes and identical consensus sequences. The ease of library preparation for metagenomic 351 
and TE sequencing of HCV was considered a major advantage for clinical sequencing, but PCR 352 
may still be appropriate for very low virus load samples. 353 
Similar results were achieved in a study comparing norovirus sequencing from PCR amplicons 354 
and target enrichment89. TE generated 100% genome coverage in 164/164 samples, while PCR-355 
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based capsid sequencing was only possible in 158/164 samples, with PCR failures attributable 356 
to low virus titres and PCR primer mismatches, suggesting TE is more sensitive than PCR for 357 
norovirus sequencing and better accommodates between-strain sequence heterogeneity89. TE 358 
has also been used as a fall-back method for samples with lower virus loads which do not give 359 
WGS after metagenomic sequencing103. Both metagenomic and TE methods have the 360 
advantage that they are applicable to all size pathogen genomes, whereas PCR based methods 361 
are less tractable for sequencing larger viral genomes or for non-viral (e.g. bacterial, fungal, 362 
parasite) pathogen genomes. 363 
These direct comparisons of different methods26,89 will be important in demonstrating the 364 
situations in which each method should be used, based on their sensitivity and specificity, as 365 
well as factors which are relevant to clinical diagnostic labs such as cost, scalability and turn-366 
around time (summarised in Table 1). 367 
 368 
Challenges of analysis and interpretation 369 
Beyond the technical challenges of method choice for viral WGS, there are a number of other 370 
roadblocks which may slow the advance of WGS in the clinic. They may be considered in three 371 
groups: ethical issues, including incidental host and microbiological findings; regulatory 372 
issues, such as the establishment of standards, good laboratory practice and sensitivity and 373 
specificity thresholds for sequencing; and analytical issues, regarding data interpretation and 374 
the proliferation of analysis options. 375 
 376 
Ethical issues and incidental findings 377 
In many clinical tests (e.g. MRI scans, host genome sequencing), there is a risk of detecting a 378 
disease association that was not part of the original investigation yet may have clinical 379 
significance for the individual or their family. These so called ‘incidental findings’ remain a 380 
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topic of intense medical ethical debate104.  The risk of incidental findings in pathogen 381 
sequencing (e.g. discovery of HIV infection during metagenomic sequencing for other 382 
pathogens) is not unique and has been resolved in clinical virology laboratories, where 383 
multiplex PCRs are used and only one of the tests has been requested. In these cases it is the 384 
practice of the laboratory to suppress the result that has not been requested (personal 385 
communication, J Breuer). In UK laboratories, the clinical virologist who interprets the test 386 
results is part of the team managing the patient and as such may decide to discuss an unexpected 387 
result with the physician-in-charge. Incidental host genetic findings (e.g. detection of variants 388 
that predispose to cancer risk) from a pathogen metagenomics study are not reported to the 389 
individual in the UK, because this reporting is only permissible with patient consent. In regard 390 
to both host and virus incidental findings, targeted enrichment and PCR have an advantage as 391 
they target only the pathogen of interest. The ethical and privacy concerns associated with the 392 
presence of host genetic data in publically available metagenomic datasets have been well 393 
reviewed by Hall and colleagues79 and represent a separate challenge.  394 
 395 
Regulatory challenges 396 
Regulation, as well as helping to address some of the concerns addressed above, will also be 397 
important in standardising WGS of viruses. The framework required to make viral WGS 398 
sufficiently robust and reproducible in clinical practice will come from a number of areas.  399 
The framework of laboratory accreditation and benchmark testing already available (for 400 
example CLIA in the USA, or accreditation against medical laboratory quality and competence 401 
standardisation criteria for ISO 15189) will support the development of viral WGS standards 402 
if there is sufficient pressure from hospitals, journals and funding agencies. 403 
Lessons learned from the use of PCR in diagnostics may be useful here, beginning with 404 
ensuring good clinical laboratory and molecular practices105,106. This will mean including 405 
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negative samples in every sequencing run, to assess contamination thresholds, spiking samples 406 
with a known virus to provide a sensitivity threshold and including positive controls and  407 
controls for batch-to-batch variation1077, all of which will increase sequencing costs and are 408 
likely to deter adoption of pathogen genome sequencing by laboratories sequencing small 409 
batches of samples. The result may be to drive centralisation of virus WGS to ensure adequate 410 
standards are kept, ensure large batches of samples and keep costs down.  411 
The issues of sensitivity and contamination are especially important in WGS because of the 412 
risk of both false-negative and false-positive detection of pathogens. Highly sensitive 413 
sequencing (whether metagenomic, PCR or TE based) may detect low-level contaminating 414 
viral nucleic acid (reviewed in108,109). For example murine leukaemia virus110,111 and 415 
parvovirus-like sequences112,113 are just two of many contaminants that have been recognised 416 
to come from common laboratory reagents such as nucleic acid extraction columns114.  As with 417 
other highly sensitive technologies, robust laboratory practices and protocols are needed to 418 
minimize contamination.  It is also important to remember that detection of viral nucleic acid 419 
does not necessarily identify the cause of illness, and it is good practice when using NGS 420 
methods for diagnosis of viral infections to confirm the findings with alternative, independent 421 
methods which do not rely on nucleic acid testing.  For example in cases of encephalitis of 422 
unknown origin, positive NGS findings can be confirmed by immunohistochemical analysis of 423 
the affected tissue59,115, or identification of the virus by electron microscopy or tissue culture79.   424 
The standardisation of methods, including bioinformatics approaches will be key to the 425 
successful use of NGS and WGS in clinical virology. Software packages that use a graphical 426 
user interface (GUI) rather than requiring command-line expertise, with strict version control 427 
of software and analysis pipelines to make results reproducible, best practices easily shareable, 428 
and to allow accreditation of analysis software will be necessary, whilst retaining an 429 
appreciation that best-practice analysis methods are continually evolving and prematurely 430 
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standardising in an overly rigid manner may inhibit innovation. Commercialisation and 431 
regulation may help, providing financial and regulatory incentives to ensure that analysis tools 432 
and technologies meet the needs of clinical sequencing for virology. Finally for drug resistance, 433 
the development of well curated databases of which mutations are truly indicative of drug 434 
resistance will be critical for accurate clinical interpretation. Such databases have already been 435 
created for HIV116, HBV117,118 and HCV119, but without recognition of their value by funding 436 
agencies, and corresponding centralised funding to ensure their continued maintenance and 437 
upkeep, tools may become swiftly outdated or unusable. 438 
 439 
Financial barriers to the use of viral WGS in a clinical setting 440 
While there are good reasons for sequencing whole genomes, and the general use of NGS, if 441 
diagnostic or hospital-based laboratories are to be persuaded to make the transition away from 442 
sequencing sub-genomic fragments, they need to see not only that the additional information 443 
gained from WGS is really of benefit to patient care; but that WGS is (or will become) as 444 
scalable and automatable as sub-genomic fragment sequencing, that the regulatory framework 445 
is suitable and that the price of sequencing whole genomes is competitive with sequencing 446 
fragments.  447 
Currently the costs of sequencing viral genomes, notwithstanding their small size, remain 448 
generally higher than sequencing of sub-genomic target resistance genes. Equally, whole 449 
genome information may provide important additional knowledge, as discussed above. The 450 
cost difference between sequencing a target region and the whole virus genome is largely 451 
governed by the size of the genome versus the size and number of target loci. 452 
 453 
What does the future hold? Long-read sequencing and host depletion 454 
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Current generation NGS technologies based around Illumina, 454, Ion Torrent or Sanger 455 
methodologies as described above have the ubiquitous problem of generating short-read data 456 
which presents challenges for haplotype phasing of intra-host minor variants, which aims to 457 
identify whether a set of genetic variants occur on the same genetic background (clonal 458 
population) or on related, highly-similar but different genetic backgrounds within the same 459 
population (sometimes called a viral swarm or cloud); as well as sequencing across repetitive, 460 
recombinatorial or mobile genetic regions which are more difficult to resolve using short reads 461 
due to problems such as mapping ambiguities. The clinical implications of understanding 462 
whether, for example, multi-drug resistance occurs on a clonal genetic background or in a 463 
mixed population of viruses with different drug resistance profiles is currently unclear.  464 
While there are computational tools (e.g.120) to help resolve these issues, especially of interest 465 
to researchers, there are also new technologies available. Newer single molecule sequencers 466 
such as PacBio (Pacific Biosciences) and MinION (Oxford Nanopore) are capable of extremely 467 
long read sequencing, and in some cases whole viral sequences (for example viruses with 468 
genomes under 20kb, such as Ebola virus, norovirus and influenza A) could theoretically be 469 
obtained from single reads. The MinION also has the advantage of being very fast, taking in 470 
some cases as little as four hours to go from sample receipt to reporting of analysed data121. 471 
Data on viral read lengths achieved from MinION sequencing have been relatively modest (e.g. 472 
mean read lengths of: 751bp (Modified Vaccinia Ankara), 758bp (cowpox virus)122, 455bp 473 
[range 126–1477] (chikungunya virus), 358bp [220–672] (Ebola virus), 1576bp123 or 6895bp 474 
(HCMV)[personal communication, M Beale] and 572bp [range 318–792] (HCV)124). Results 475 
from the better-established PacBio technology are more promising, including a recent report 476 
of a pseudorabies virus genome sequenced with a mean read length of 12,777bp (against a 477 
double-stranded DNA genome ~142kp in length)125, and 9.2kb reads have been achieved in 478 
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PacBio HCV genome sequencing (where only 9.2kb of the 9.6kb had been pre-amplified by 479 
PCR)126.  480 
A drawback of both NGS and single-molecule sequencing however is the need for high 481 
coverage to minimize the impact of sequencing errors, particularly in the context of drug 482 
resistance studies, as drug resistance most frequently results from single nucleotide mutations 483 
or small deletions (1-3 bases), especially in lower-fidelity RNA viruses127. This can be a 484 
challenge where the amount of viral genome is dwarfed by the presence of host DNA, and 485 
when the error profile of a technology makes point mutations particularly hard to detect 486 
accurately121. At the time of writing, MinION sequencing (R9 pore chemistry) has raw 2D read 487 
error rates of ~5% [personal communication, Josh Quick], which compares unfavourably with 488 
Illumina (<0.1%), Ion Torrent (~1%) and PacBio (13% single pass, <1% with circular 489 
consensus read) error rates128.  490 
However, demonstration of the potential for using these long read technologies with target 491 
enrichment provides a potential way forward123,129, as ambiguities can be resolved if sufficient 492 
depth of sequence is achieved for the target pathogen, and errors rates for all methodologies 493 
may be reduced with technological and analytical improvements. Products or methods which 494 
can deplete the host genetic background but not the viral nucleic acids within a sample would 495 
be an alternative solution, meaning  a higher proportion of virus reads would be recovered from 496 
each sequencing run. While there are already solutions in place for bacterial sequencing (e.g. 497 
human ribosome RNA or mitochondrial depletion, selective depletion of DNA with a certain 498 
methylation pattern), there are no dedicated products for viral sequencing. 499 
 500 
Conclusion 501 
Whole virus genome sequencing is of growing importance in a clinical context, for diagnosis, 502 
disease management and molecular epidemiology (including infection control).  There are a 503 
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number of methods available to achieve WGS of viruses from clinical samples. Currently the 504 
choice of methodology (amplicon sequencing, target enrichment or metagenomics) is specific 505 
to both the virus and the clinical question. Metagenomic sequencing is most appropriate for 506 
diagnostic sequencing of unknown or poorly characterised viruses, PCR works well where viral 507 
genomes are short and diversity in primer binding sites is low, while target enrichment works 508 
for all pathogen sizes, but is particularly advantageous for large viruses and for viruses with 509 
diverse but well characterised genomes. Two obvious areas of innovation currently exist: firstly 510 
for methods that can effectively deplete host DNA whilst preserving viral DNA, and secondly 511 
for further development in the long-read technology market in order to achieve the range of 512 
flexibility and competitive pricing that exists in the short-read market. New technologies are 513 
needed to unite the strengths of these different methods and allow healthcare providers to invest 514 
in a single technology which is suitable for all viral WGS applications.  515 
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Box 1. RNA-seq and metagenomics diagnostics. 534 
BOX:RNASEQ AND METAGENOMICS DIAGNOSTICS 
In cases of encephalitis of unknown origin, metagenomic techniques are becoming 
increasingly promising diagnostic tools. There are a variety of protocols in use, but the 
clearest distinction is between RNA-seq and metagenomics. RNA-seq is the sequencing of 
either the total RNA or a subset of RNA extracted from a sample (cerebrospinal fluid or 
brain biopsy, for example), converted to cDNA and sequenced. Metagenomics is generally 
used to describe the same procedure for DNA, but may also include simultaneous sequencing 
of DNA and RNA by incorporating a cDNA synthesis step. RNA-seq methodologies may 
improve detection of pathogenic viruses, as many viruses have RNA genomes; the 
expression of viral genes in the CSF or brain is indicative of both the presence of the virus, 
and which viral genes are being transcribed. However, DNA viruses which experience low-
level transcription may be poorly detected using RNA-seq and read numbers for DNA 
viruses may be higher in metagenomic datasets64. 
Both methods have successfully identified new or known viral pathogens implicated in 
encephalitis of unknown origin. Metagenomics has been used to aid in diagnosis and 
characterisation of enterovirus D68 in cases of acute flaccid paralysis80. Metagenomics 
identified herpesviruses in the CSF of four patients with suspected viral 
meningoencephalitis130. RNA-seq also successfully identified HSV1 in an encephalitis case, 
although the use of a DNAse I digestion (intended to lower the amount of host nucleic acid 
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in the subsequent sequencing library) lowered the number of HSV1 reads64. Mumps vaccine 
virus has also been detected a chronic encephalitis case using RNAseq [Morfopoulou, S. 
Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic 
encephalitis. Acta Neuropathologica (In Press.)].  
RNA-seq has been very successful in identifying encephalitis caused by astroviruses131,132 
and coronaviruses59. The deaths of three squirrel breeders from encephalitis was linked to a 
novel squirrel bornavirus through the use of a metagenomic protocol in which DNA and 
RNA were separately extracted and sequenced as discrete libraries, providing 
complementary data63. Ultimately, metagenomics provides more information about the virus 
genome present in a sample than PCR alone, which may be important for molecular 
epidemiology, while RNA-seq has the power to selectively capture information on which 
sequences are present, as well as informing researchers about viral gene expression of 
relevance to pathology.  
 535 
Box 2: The role of whole-genome sequencing in Zika virus epidemiology and infection control 536 
Box 2: The role of whole-genome sequencing in Zika virus epidemiology and infection 
control 
Zika whole-genome sequencing is being used to understand the epidemiology of the 
outbreak (where did the virus come from? When did it enter Brazil?); to understand the 
connection between the virus and microcephaly; and to inform control measures, by stopping 
importation or interrupting transmission from a reservoir, and informing blood safety 
measures in hospitals, for example by demonstrating transfusion transmissibility of the virus.  
Whole-genome (or near whole-genome) sequence is required from flavivirus genomes to 
give molecular epidemiology studies sufficient power41. WGS, phylogenetic analysis and 
molecular clock dating, combined with other epidemiological data, were useful in excluding 
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hypotheses about the introduction of Zika virus to South America41. For example, the most 
recent common ancestor of strains circulating in Brazil predates the 2014 football World 
Cup, making it highly unlikely that this event was responsible for introducing Asian-lineage 
Zika virus to South America41. 
WGS is also central to understanding Zika virus pathogenesis, and could be used to 
interrogate the whole genome of Zika virus for changes associated with microcephaly, as not 
enough of the virus’s biology is currently understood to allow studies to limit themselves to 
smaller regions of the genome. It’s likely that a wide sample of Zika whole genome 
sequences, from around the world and from microcephaly and asymptomatic cases, will be 
needed to be give confidence to any studies linking particular mutations to the birth defects 
seen in the recent Zika virus outbreak. No changes in the Zika virus genome have yet been 
unambiguously associated with microcephaly41,69,78. 
Whole-genome and fragment sequencing were used to identify a case of probably transfusion 
transmission of Zika virus through a platelet donation. This has significant public health and 
infection control relevance as it suggests asymptomatic donors are capable of transmitting 
the virus to immunocompromised individuals, although PCR-based testing had already 
established the presence of Zika virus in the blood supply in a previous outbreak, in this case 
without molecular epidemiology to demonstrate cases of Zika virus in blood product 
recipients133. Blood products may need to be routinely screened for Zika virus134.  
Finally, whole-genome sequencing of Zika isolates has found sequence polymorphisms 
within primer-binding sites135, which may make PCR-based diagnosis and virus load 
quantification more difficult. This highlights the need to characterise population-level 
diversity, especially in epidemics, where the locally circulating virus sequence may have 
diverged significantly from related sequences from other locations or time periods. A number 
of projects are underway to achieve these goals, including the ZIBRA mobile laboratory 
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project136, employing portable metagenomic sequencing of Zika virus 
(http://zibraproject.github.io/) and real-time reporting of results103.  
 537 
Figure 1: Major methods for sequencing viral genomes from clinical specimens.   538 
All specimens originally comprise a mix of host (in blue) and pathogen (in red) sequences.  539 
Direct metagenomic sequencing provides an accurate representation of the sequences within 540 
the sample at the cost of high sequencing and data analysis/storage costs.  PCR amplicon 541 
sequencing uses many discrete PCR reactions to enrich the viral genome, significantly 542 
increasing the workload for large genomes, but reducing the sequencing costs.  Target 543 
enrichment sequencing uses virus-specific nucleotide probes bound to a solid phase to enrich 544 
the viral genome in a single reaction, reducing workload, but increasing library cost (relative 545 
to PCR). 546 
 547 
Table 1. Advantages and disadvantages of different viral sequencing sample 548 
preparation approaches 549 
 Advantages Disadvantages 
Metagenomics  Simple, cost-effective 
sample preparation 














 Preservation of minor 
variant frequencies 
 High sequencing cost to 
obtain sufficient 
pathogen sequence 
 Relatively low 
sensitivity to target 
pathogen, and coverage 
proportional to viral 
load 




 Incidental sequencing 






reflects in vivo 
variation 
 No primer/probe 
design enables rapid 








and trained staff 
 Highly specific – 
most sequencing 
reads will be 
pathogen, reducing 
sequencing costs 
 Highly sensitive, with 
good coverage 
achievable even at 
low pathogen load 
 Relatively 
straightforward to 
introduce new primer 
designs for novel 
sequences 
 Labour intensive and 
difficult to scale for 
large genomes 
 Iterating standard PCRs 
across large genomes 
requires high sample 
volume 
 PCR reactions subject 
to primer mismatch, 
particularly in poorly 
characterised or highly 
diverse pathogens, or 
those with novel 
variants 
 Limited ability to 
sequence novel 
pathogens 
 High number of PCR 
cycles may introduce 
amplification mutations 
 Uneven amplification 
of different PCR 
amplicons may 
influence minor variant 
and haplotype 
reconstruction 
Target Enrichment  Single tube sample 
preparation suited to 
high throughput 
automation and 
sequencing of large 
genomes 









 High cost and technical 
expertise for sample 
preparation 
 Unable to sequence 
novel pathogens and 
requires well 
characterised reference 
genomes for probe 
design 
 Sensitivity is 
comparable to PCR but 
coverage is 
proportional to 
pathogen load – low 




Table 2. Limitations of viral sequencing 551 








Different extraction protocols for different 
viruses, use of cDNA synthesis in RNA 
viruses or second strand synthesis for 




















Lack of conserved homology between 
viral phyla prevents universal primer 
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replication 
Cultured virus is heavily contaminated 
with host cell genome/transcriptome, 
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Clinical specimens are heavily 
contaminated with host 
genome/transcriptome, reducing 
equivalent viral sequencing output 
 Reduced number of 
PCR cycles (relative 




 Preservation of minor 
variant frequencies 




 Cost and time to 
generate new probe sets 






































DNA digestion according to methylation 
patterns is less effective as a means of 
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